FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2023
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca cell & gene therapy deal w/ Cellectis
01 November 2023
AstraZeneca announces collaboration and investment agreement with
Cellectis to accelerate cell therapy and genomic medicine
ambitions
Collaboration leverages the Cellectis gene editing technologies and
manufacturing capabilities, to develop up to 10 novel cell and gene
therapy candidate products
AstraZeneca today announced a collaboration and investment
agreement with Cellectis, a clinical-stage biotechnology company,
to accelerate the development of next generation therapeutics in
areas of high unmet need, including oncology, immunology and rare
diseases.
Under the terms of the collaboration agreement, AstraZeneca will
leverage the Cellectis proprietary gene editing technologies and
manufacturing capabilities, to design novel cell and gene therapy
products, strengthening AstraZeneca's growing offering in this
space. As part of the agreement, 25 genetic targets have been
exclusively reserved for AstraZeneca, from which up to 10 candidate
products could be explored for development.
Marc Dunoyer, Chief Strategy Officer, AstraZeneca, and Chief
Executive Officer, Alexion, AstraZeneca Rare Disease, said:
"The differentiated capabilities Cellectis has in gene editing and
manufacturing complement our in-house expertise and investments
made in the past year. AstraZeneca continues to advance our
ambition in cell therapy for oncology and autoimmune diseases as
well as in genomic medicine, which has potential to be
transformative for patients with rare diseases."
André Choulika, PhD, Chief Executive Officer of Cellectis,
said: "We believe AstraZeneca is the perfect match to Cellectis by
providing world-class expertise in the development and the
commercialisation of innovative medicines. This collaboration will
allow us to leverage our pioneering research in gene editing and
cell therapies, as well as our cutting-edge capabilities in
manufacturing with the ambition to bring potentially life-saving
therapies to patients with unmet medical need."
Building on AstraZeneca's own expertise in cell and genomic
therapy, the Company has enhanced its capabilities through several
collaborations and investments in the past year as part of its
ambition to bring cell therapies to more patients living with
cancer and to advance genomic medicines for rare
diseases.
Financial considerations
In Q4 2023, Cellectis will receive an initial payment of $105m from
AstraZeneca, which comprises a $25m upfront cash payment under the
terms of a research collaboration agreement and an $80m equity
investment.
The initial equity investment of $80m, at $5/share, represents an
equity stake of c. 22% in Cellectis. A further $140m equity
investment, at $5/share, is expected to close in early 2024 subject
to the signing of a final binding agreement
following completion of a consultation with the Cellectis
employee representative bodies and customary closing conditions
including Cellectis shareholders' approval and regulatory
clearances. Post-closing of this second investment, AstraZeneca
will hold a total equity stake of c. 44% in Cellectis. AstraZeneca
expects to treat its investment in Cellectis as an
associate.
Under the terms of the research collaboration, Cellectis is also
eligible to receive an investigational new drug (IND)
option fee and development, regulatory and sales-related milestone
payments, ranging from $70m up to $220m, per each of the 10
candidate products, plus tiered royalties.
AstraZeneca retains an option for a worldwide exclusive license for
the candidate products developed under the research collaboration
agreement, to be exercised before IND filing.
Notes
Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca
focused on rare diseases, created following the 2021 acquisition of
Alexion Pharmaceuticals, Inc. As a leader in rare diseases for
nearly 30 years, Alexion is focused on serving patients and
families affected by rare diseases and devastating conditions
through the discovery, development and commercialisation of
life-changing medicines. Alexion focuses its research efforts on
novel molecules and targets in the complement cascade and its
development efforts on haematology, nephrology, neurology,
metabolic disorders, cardiology and ophthalmology. Headquartered in
Boston, Massachusetts, Alexion has offices around the globe and
serves patients in more than 50 countries.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition
to provide cures for cancer in every form, following the science to
understand cancer and all its complexities to discover, develop and
deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It
is through persistent innovation that AstraZeneca has built one of
the most diverse portfolios and pipelines in the industry, with the
potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
01 November 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (PK) (USOTC:AZNCF)
Historical Stock Chart
From Dec 2024 to Jan 2025
AstraZeneca (PK) (USOTC:AZNCF)
Historical Stock Chart
From Jan 2024 to Jan 2025
